F2 and hyperhomocysteinemia: The combination of oral contraceptive medication and genetic thrombophilia significantly increases the risk of CVT, especially in women with factor V Leiden mutation, prothrombin gene mutation, and hyperhomocysteinemia [17,18,19,20].